Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • Bafilomycin A1 targets patient...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

Bafilomycin A1 targets patient-derived CD34+CD19+ leukemia stem cells

Bibliographic Details
Published in:Haematologica
Main Authors: Li Xu, Na Yuan, Hong Liu, Yixuan Fang, Chaorong Ge, Fei Xu, Ni An, Wen Wei, Lei Li, Li Ji, Xiaoying Zhang, Jiahao Meng, Suping Zhang, Yun Zhao, Zixing Chen, Suning Chen, Depei Wu, Jianrong Wang
Format: Article
Language:English
Published: Ferrata Storti Foundation 2020-01-01
Online Access:https://haematologica.org/article/view/9498
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://haematologica.org/article/view/9498

Similar Items

  • Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia
    by: Na Yuan, et al.
    Published: (2015-03-01)
  • Integration of CD34+CD117dim population signature improves the prognosis prediction of acute myeloid leukemia
    by: Xue-Ping Li, et al.
    Published: (2022-08-01)
  • Rapamycin and bafilomycin A1 alter autophagy and megakaryopoiesis
    by: Qi Wang, et al.
    Published: (2017-01-01)
  • Evaluation of Cell Biomarker Gene Expression (CD34) in ALL Patients and Healthy Controls Expression (CD34) in People with Leukemia
    by: goolshan moradozadeh, et al.
    Published: (2020-08-01)
  • The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia.
    by: Runxia Gu, et al.
    Published: (2017-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs